Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Molecular Cancer

Figure 4

From: Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

Figure 4

(a) Fold increases (mean ± SD) in infectious progeny virion production determined by plaque assay in NCI-H460, NCI-H23, EKVX and HOP-92 treated with the combination of ReoT3D (MOI = 20) and paclitaxel (1 μM for NCI-H460 and NCI-H23 and 10 μM for EKVX and HOP-92 cells) for 24 hours as compared to ReoT3D alone (MOI = 20). Paclitaxel invariably increased the level of virion production from all the cell lines tested. (b) Fold increases (mean ± SD) in infectious progeny virion production in NCI-H23, EKVX and NCI-H322M treated with ReoT3D (MOI = 20) in combination with paclitaxel (0.1 μM for NCI-H23 and 1 μM for EKVX and NCI-H322M), gemcitabine (0.1 μM for NCI-H23 and 1 μM for EKVX and NCI-H322M) or vinblastine (10 nM for NCI-H23 and 100 nM for EKVX and NCI-H322M) for 24 hours as compared to ReoT3D alone (MOI = 20). Note the increased virion production in the presence of tubulin-binding agents, paclitaxel or vinblastine, but not with gemcitabine. Asterisks denote statistical significance (P < 0.05).

Back to article page